...Ya-Sian Chang; Shun-Jen Chang; Kun-Tu Yeh; Tsai-Hsiu Lin; Jan-Gowth Chang Background: Colorectal cancer (CRC) plays an important role in cancer mortality and morbidity. This study examined colorectal tissues for RAS , BRAF , and TP53 gene mutations to assess their value as indicators of outcomes...

...Ke-Qing Shi; Zhuo Lin; De-Wei Li; Yu-Xiao Fang; Jian Gao; Zhu-Jun Deng; Li Chen; Gui-Ling Li; Jian-Min Wu; Kai-Fu Tang Background/Aims: To accurately evaluate the impact of the C/T polymorphism in microRNA (miRNA)-196a2 on the colorectal cancer (CRC) risk, by meta-analysis. Methods: An electronic...

...), a fully human monoclonal antibody to the epidermal growth factor receptor (EGFR), was developed as a therapeutic option for metastatic colorectal cancer (mCRC) in patients with a wild-type KRAS gene [ 1 ]. Common adverse effects include skin toxicity, diarrhea, and hypomagnesemia; these adverse effects...

...Christian Neumaier; Stefanie Nittka; Michael Neumaier According to their carcinogenesis, colorectal cancer (CRC) subtypes show distinct molecular parameters. Hereditary non-polypous colorectal cancer (HNPCC) is the most common inherited CRC characterized by clinical criteria and confirmed...

... liver metastases of colorectal cancer (CRC). Patients and Methods: Individual patients were treated with irinotecan (120 mg/m 2 ), oxaliplatin (100 mg/m 2 ), and floxuridine (500 mg/m 2 ) via tumorsupplying arteries. Intravenous leucovorin (200 mg/day) and floxuridine (300 mg/m 2 /day) were given...

...Gregor Weißflog; Susanne Singer; Alexandra Meyer; Christian Wittekind; Arne Dietrich; Arved Weimann; Elmar Brähler; Jochen Ernst Background: Since 2006, in Germany colorectal cancer patients can be treated in certified colorectal cancer centers. The aim of this explorative study was to investigate...

...Zhi-Ping Liu; Li-Min Li; Xiu-Li Liu; Da-Xin Zhang Background: We evaluated the feasibility of CEA/CK20 mRNA and CEA/CA19-9 proteins as tumor markers for colorectal cancer by detecting tumor-specific mRNAs in circulating tumor cells and secreted tumor-specific proteins in the peripheral blood...

...Dirk Arnold; Alexander Stein In the last 15 years, significant progress in the management of colorectal cancer (CRC) has been achieved with several new agents licensed extending median overall survival for stage IV disease to about 2 years. Treatment of CRC is stage-specific, multidisciplinary...

...Monika Engelhardt; Gabriele Ihorst; Josefina Udi; Martina Kleber; Justyna Rawluk; Ralph Wäsch Background: Ulcerative colitis (UC) patients may develop colorectal cancer (CRC), especially with pancolitis and longer UC duration. The question whether CRC with underlying UC has a dismal prognosis...

..., instructions or products referred to in the content or advertisements. Chemokines Invasion Colorectal cancer Plerixafor Original Article · Originalarbeit Onkologie 2011;34:502 508 DOI: 10.1159/000332390 Published online: September 20, 2011 A Lentiviral CXCR4 Overexpression and Knockdown Model...

... of the heterozygous variant (677CT) but not that of 677TT was found to be significantly higher in colorectal cancer cases than in controls (p < 0.039; odds ratio 2.35 and 95% confidence interval 1.02–5.415). The frequencies for 677CT were 11.0 and 5.0% in colorectal cancer samples and controls, respectively...

...Andrew K. Chan; Bok A. Choo; John Glaholm Background: Oxaliplatin in combination with either 5-fluorouracil or capecitabine is commonly used in the treatment of colorectal cancer and is rarely associated with pulmonary toxicity. This is the first reported case of oxaliplatin and capecitabine/5...

...Konstantinos P. Economopoulos; Theodoros N. Sergentanis; Flora Zagouri; George C. Zografos Background: This meta-analysis on case-control studies aims to examine whether the p53 Arg72Pro polymorphism is associated with colorectal cancer risk, addressing also whether the effect of the polymorphism...

... the efficacy and toxicity of weekly and biweekly irinotecan-based chemotherapies and their compatibility depending on age. Methods: 601 patients with advanced or metastatic colorectal cancer receiving first-, second-, or third-line irinotecanbased therapy were regularly analyzed for response and toxicity until...

... thrombotic endocarditis Colorectal cancer Colon adenocarcinoma Case Report · Kasuistik Onkologie 2010;33:456 459 DOI: 10.1159/0003173423 Published online: July 7, 2010 Nonbacterial Thrombotic (Marantic) Endocarditis in a Patient with Colorectal Cancer Panagiotis J. Vlachostergiosa Danai D. Daliania...

... and irinotecan (OCX) in metastatic colorectal cancer. Patients and Methods: Patients with performance status (PS) < 2 and adequate haematological, renal and liver function received oxaliplatin 70 mg/m 2 on days 1 and 15, irinotecan 100 mg/m 2 on days 8 and 22 and one of five dose levels (DL 1–5, between 800...

... advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Liver metastases Colorectal cancer HIV...

... in combination with capecitabine in patients with advanced colorectal cancer (aCRC). Patients and Methods: After failure of a 1st-line therapy, patients with aCRC received escalating doses of gefitinib once daily in combination with capecitabine twice daily: dose level (DL) 1: gefitinib 250 mg and capecitabine...

...; Umberto Tirellia Background: Data on colorectal cancer (CRC) in HIV-positive patients are limited. The study objective was to investigate and compare clinical presentation and outcome between HIV-positive and HIV-negative CRC patients. Patients and Methods: Between September 1985 and November 2003 we...

...H.-J. Schmoll; T. Büchele; C. Schöber Only a few years ago it was still a debate, whether patients with advanced colorectal cancer should be treated by a palliative chemotherapy at all. After the demonstration of a palliative benefit of these patients in terms of prolongation of time to progression...